Russell Investments Group Ltd. Grows Holdings in Capricor Therapeutics Inc (NASDAQ:CAPR)

Russell Investments Group Ltd. grew its stake in shares of Capricor Therapeutics Inc (NASDAQ:CAPR) by 172.8% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,652 shares of the biotechnology company’s stock after buying an additional 2,947 shares during the quarter. Russell Investments Group Ltd.’s holdings in Capricor Therapeutics were worth $64,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in CAPR. Vanguard Group Inc. increased its stake in Capricor Therapeutics by 44.4% in the fourth quarter. Vanguard Group Inc. now owns 2,276,784 shares of the biotechnology company’s stock valued at $31,420,000 after acquiring an additional 700,243 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Capricor Therapeutics by 37.8% during the 4th quarter. Geode Capital Management LLC now owns 879,468 shares of the biotechnology company’s stock valued at $12,139,000 after buying an additional 241,279 shares in the last quarter. State Street Corp lifted its position in Capricor Therapeutics by 27.8% in the 3rd quarter. State Street Corp now owns 512,313 shares of the biotechnology company’s stock worth $7,792,000 after buying an additional 111,291 shares during the last quarter. Black Diamond Financial LLC purchased a new stake in Capricor Therapeutics in the fourth quarter worth approximately $3,833,000. Finally, Charles Schwab Investment Management Inc. grew its position in Capricor Therapeutics by 51.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 111,336 shares of the biotechnology company’s stock valued at $1,536,000 after acquiring an additional 37,868 shares during the last quarter. 21.68% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. HC Wainwright restated a “buy” rating and issued a $77.00 price objective on shares of Capricor Therapeutics in a report on Monday, March 17th. Cantor Fitzgerald reissued an “overweight” rating and issued a $30.00 price target on shares of Capricor Therapeutics in a research note on Thursday, March 20th. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company. According to data from MarketBeat, Capricor Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $34.50.

Capricor Therapeutics Stock Down 1.9 %

Shares of CAPR opened at $13.03 on Friday. The stock has a market capitalization of $595.17 million, a P/E ratio of -12.29 and a beta of 4.65. Capricor Therapeutics Inc has a twelve month low of $3.52 and a twelve month high of $23.40. The firm has a fifty day simple moving average of $12.09 and a two-hundred day simple moving average of $14.84.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings results on Wednesday, March 19th. The biotechnology company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.15. The business had revenue of $11.13 million for the quarter, compared to analysts’ expectations of $9.87 million. Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. Sell-side analysts expect that Capricor Therapeutics Inc will post -1.21 EPS for the current fiscal year.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.